Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
Jun 9, 2026 9:23 AM
It'll be the first time ER-100 technology to reverse cellular aging will be tested on a humans.
Photo-Illustration: WIRED Staff; Getty Images
A longevity startup has dosed its first patient with a drug to reverse age-related sight loss.
Life Biosciences is testing its ER-100 drug, which has been shown to restore vision in monkeys, for safety and side effects in a study of around 18 adults over the next year.
It will be targeting patients with glaucoma and NAION, two conditions causing damage to crucial cells in the optic nerve, which transmits visual information from the back of the eye to the brain. ER-100 is designed to rejuvenate those cells so that they work again and restore sight.
It is the first ever cellular rejuvenation therapy using this technology to receive FDA clearance to enter human clinical trials, and hence the first chance to test...
Copyright of this story solely belongs to wired.com. To see the full text click HERE
